About Xlife sciences
Xlife sciences is a company based in Zurich (Switzerland) founded in 2013. Xlife sciences has raised $62.81 million across 2 funding rounds. Xlife sciences has completed 1 acquisition, including Fuse AI. Xlife sciences offers products and services including Technology Platforms and Biotech Projects. Xlife sciences operates in a competitive market with competitors including CELLINK, Aspect Biosystems, OxSyBio, Collplant and Cyfuse, among others.
- Headquarter Zurich, Switzerland
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Xlife Sciences Ltd.
-
Annual Revenue
$921.54 K (USD)-15.54as on Dec 31, 2024
-
Net Profit
$37.84 M (USD)130.37as on Dec 31, 2024
-
EBITDA
-$4.04 M (USD)16.53as on Dec 31, 2024
-
Total Equity Funding
$62.81 M (USD)
in 2 rounds
-
Latest Funding Round
$6.7 M (USD), Series C
Dec 03, 2020
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Xlife sciences
Xlife sciences is a publicly listed company on the SIX with ticker symbol XLS in Switzerland, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Xlife sciences
Xlife sciences offers a comprehensive portfolio of products and services, including Technology Platforms and Biotech Projects.
Platforms for advancing life science research and commercialization projects.
Development of biotechnologies for medical needs and patient treatments.
People of Xlife sciences
Unlock access to complete
Unlock access to complete
Funding Insights of Xlife sciences
Xlife sciences has successfully raised a total of $62.81M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $6.7 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Xlife sciences
Xlife sciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fuse AI.
Investment portfolio details for Xlife sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-enabled diagnostics for medical images are provided to radiologists.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Xlife sciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Xlife sciences
Detailed financials for Xlife sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xlife Sciences Comparisons
Peer comparison for Xlife sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xlife sciences
Xlife sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CELLINK, Aspect Biosystems, OxSyBio, Collplant and Cyfuse, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Bioprinting technology and tissue therapeutics for regenerative medicine are developed.
|
|
| Locked | Locked | Locked |
Provider of 3D printing of tissue biomaterials for medical research and clinical applications
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
3D tissue engineering technology is developed for regenerative medicine applications.
|
|
| Locked | Locked | Locked |
Developer of integrated 3D printing and tissue-engineering platform
|
Detailed competitors of Xlife sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xlife Sciences
Complete news archive for Xlife sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xlife sciences
Xlife sciences was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Xlife sciences is headquartered in Zurich, Switzerland.
Oliver R Baumann is the current CEO of Xlife sciences.
Xlife sciences is a funded company, having raised a total of $62.81M across 2 funding rounds to date.
Annual revenue of Xlife sciences is $921.54K as on Dec 31, 2024.
Xlife Sciences was founded in 2013 and is based in Zurich, Switzerland. Focus is placed on the biotechnology sector, where therapeutics for various indications are developed, such as antibody therapies for obesity and acute lymphocytic leukemia, as well as nanovesicle therapies for arthritis. Additional services provided include 3D bioprinting and AI-based software for cancer diagnosis. Operations center on drug development and related platform services.
Xlife sciences's top competitors include Aspect Biosystems, Cyfuse and Collplant.
Xlife sciences offers Technology Platforms and Biotech Projects.
Yes, Xlife sciences is publicly traded on SIX under the ticker symbol XLS.
Xlife sciences has made 1 acquisition, including Fuse AI.
The ticker symbol of Xlife sciences is XLS on SIX.